Dosage Forms and Strengths
DOSAGE FORMS AND STRENGTHS
... If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that discontinuation can be associated with certain symptoms [see Dosage and ...
31
DOSAGE FORMS AND STRENGTHS
... Local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT (7.2% versus 5.1% for [r] ...
16
3 DOSAGE FORMS AND STRENGTHS
... In clinical studies, establishing the safety and efficacy of LATUDA, patients were instructed to take their daily dose with food [see Dosage and Administration (2.3)]. Metabolism and Elimination: LATUDA is ...
16
DOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION
... The following table lists adverse reactions (all Grades) that occurred with at least 3% higher frequency among subjects receiving OLYSIO 150 mg once daily in combination with Peg-[r] ...
48
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS
... 5.5 Renal Impairment In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis. Some ...
56
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS
... The entire contents of each packet of oral granules should be mixed with one teaspoon (5 mL) of age-appropriate soft food or liquid and completely consumed. Food or liquid should be at or below room temperature. Once ...
16
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS
... Treatment-naïve Subjects: In SINGLE, 833 adult subjects were randomized and received at least one dose of either dolutegravir (TIVICAY) 50 mg with fixed-dose abacavir sulfate and lamiv[r] ...
42
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS ADVERSE REACTIONS
... 8.5 Geriatric Use In controlled clinical trials comparing LEVEMIR ® to NPH insulin or insulin glargine, 64 of 1624 patients (3.9%) in the type 1 diabetes trials and 309 of 1082 patients (28.6%) in the type 2 diabetes ...
11
DOSAGE FORMS AND STRENGTHS CLARINEX Tablets - 5 mg (3)
... of the 14 C-desloratadine dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3- hydroxydesloratadine showed similar T max and half-life values compared to desloratadine. ...
10
DOSAGE FORMS AND STRENGTHS Tablets: 100 mg, 300 mg (3)
... At the of end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C (p<0.001 for both doses) compared to placebo when added[r] ...
41
DOSAGE FORMS AND STRENGTHS. Oral solution: 100 mg/ml (3)
... 20 and 25 mg/kg/day, respectively. 8.5 Geriatric Use Clinical trials of EPIDIOLEX in the treatment of LGS, DS, and TSC did not include a sufficient number of patients aged above 55 years to determine whether or not they ...
Page 1 of 20 FULL PRESCRIBING INFORMATION: CONTENTS* DOSAGE FORMS AND STRENGTHS
... LINZESS is contraindicated in pediatric patients up to 6 years of age; in nonclinical studies, administration of a single, clinically relevant adult oral dose of linaclotide caused dea[r] ...
20
DOSAGE FORMS AND STRENGTHS mg/1 ml single use vial (3).
... pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)]. Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath ...
17
Page 1 of DOSAGE FORMS AND STRENGTHS Tablets: 5 mg and 10 mg (3)
... In a study of 24 weeks duration, 404 patients with moderate to severe probable Alzheimer’s disease (diagnosed by NINCDS-ADRDA criteria, with Mini-Mental State Examination scores ≥ 5 [r] ...
19
DOSAGE FORMS AND STRENGTHS Tablets: 75 mg, 150 mg, 300 mg (3)
... The Irbesartan Diabetic Nephropathy Trial (IDNT) was a randomized, placebo- and active-controlled, double-blind, multicenter study conducted worldwide in 1715 patients with type 2 diabet[r] ...
5
DOSAGE FORMS AND STRENGTHS For Injection: 3 mg/ml in single-dose vials (3)
... 2 DOSAGE AND ADMINISTRATION The recommended Adenoscan dose is 0.14 mg/kg/min infused over six minutes (total dose of 0.84 mg/kg) (Table 1). • Administer Adenoscan only as a continuous peripheral intravenous ...
9
Page 1 of DOSAGE FORMS AND STRENGTHS Delayed-Release Capsules: 3 mg (3)
... The recommended dosage of ENTOCORT EC for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon in adults is 9 mg once daily in the mo[r] ...
27
DOSAGE FORMS AND STRENGTHS For injection: 250 mg of bivalirudin in a single-dose vial for reconstitution. (3)
... In 4312 patients undergoing PTCA for treatment of unstable angina in 2 randomized, double- blind studies comparing Angiomax to heparin, Angiomax patients exhibited lower rates of major [r] ...
20
DOSAGE FORMS AND STRENGTHS Capsules: 1 mg, 2 mg, 3 mg, and 4 mg (3)
... different forms of contraception, including at least 1 highly effective form, simultaneously during POMALYST therapy, during therapy interruption, and for 4 weeks after she has completely finished taking ...
32
DOSAGE FORMS AND STRENGTHS Intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR solid polymer drug delivery system.
... Plasma concentrations were obtained from 21 patients with macular edema due to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and 21 patients with diabe[r] ...
12